We are live on
!
Find out more
Atossa Therapeutics
ATOS
ATOS
92 hedge funds and large institutions have $63.2M invested in Atossa Therapeutics in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 23 increasing their positions, 28 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
65% more call options, than puts
Call options by funds: $8.73M | Put options by funds: $5.29M
0.43% more ownership
Funds ownership: 1.64% → 2.07% (+0.43%)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
1% less funds holding
Funds holding: 93 → 92 (-1)
18% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 28
38% less capital invested
Capital invested by funds: $102M → $63.2M (-$38.9M)
Holders
92
Holders Change
-1
Holders Change %
-1.08%
% of All Funds
1.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
23
Reduced
28
Closed
21
Calls
$8.73M
Puts
$5.29M
Net Calls
+$3.44M
Net Calls Change
-$16M
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$7.93M |
| 2 |
Two Sigma Investments
New York
|
+$5.56M |
| 3 |
Two Sigma Advisers
New York
|
+$3.68M |
| 4 |
Renaissance Technologies
New York
|
+$2.86M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.51M |
